The Food and Drug Administration approved IBSA's liquid form of the synthetic thyroid hormone drug levothyroxine.
Tirosint-SOL is intended to treat hypothyroidism and thyroid stimulating hormone suppression in patients with certain types of thyroid cancers.
The drug's liquid form offers an alternative treatment method for patients who can't swallow or are fed by tube, according to a news release. The drug can also be used for children with hypothyroidism.
Lugano, Switzerland-based IBSA aims to launch Tirosint-SOL in the next six months.
More articles on supply chain:
Lawmakers propose bill to revamp FDA's medical device inspections
Inova taps Omnicell for supply chain pharmacy services
Gilead buys Sarepta's priority review voucher for $125M: 3 takeaways